|
1
|
Strojan P, Popović M, Surlan K and Jereb
B: Choroid plexus tumors: A review of 28-year experience.
Neoplasma. 51:306–312. 2004.PubMed/NCBI
|
|
2
|
Sun MZ, Oh MC, Ivan ME, Kaur G, Safaee M,
Kim JM, Phillips JJ, Auguste KI and Parsa AT: Current management of
choroid plexus carcinomas. Neurosurg Rev. 37:179–192; discussion
192. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Koh EJ, Wang KC, Phi JH, Lee JY, Choi JW,
Park SH, Park KD, Kim IH, Cho BK and Kim SK: Clinical outcome of
pediatric choroid plexus tumors: Retrospective analysis from a
single institute. Childs Nerv Syst. 30:217–225. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Krishnan S, Brown PD, Scheithauer BW,
Ebersold MJ, Hammack JE and Buckner JC: Choroid plexus papillomas:
A single institutional experience. J Neurooncol. 68:49–55. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Buxton N and Punt J: Choroid plexus
papilloma producing symptoms by secretion of cerebrospinal fluid.
Pediatr Neurosurg. 27:108–111. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Samuel TA, Parikh J, Sharma S, Giller CA,
Sterling K, Kapoor S, Pirkle C and Jillella A: Recurrent adult
choroid plexus carcinoma treated with high-dose chemotherapy and
syngeneic stem cell (bone marrow) transplant. J Neurol Surg A Cent
Eur Neurosurg. 74 Suppl 1:e149–e154. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wolff JE, Sajedi M, Brant R, Coppes MJ and
Egeler RM: Choroid plexus tumours. Br J Cancer. 87:1086–1091. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bettegowda C, Adogwa O, Mehta V, Chaichana
KL, Weingart J, Carson BS, Jallo GI and Ahn ES: Treatment of
choroid plexus tumors: A 20-year single institutional experience. J
Neurosurg Pediatr. 10:398–405. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kubicky CD, Sahgal A, Chang EL and Lo SS:
Rare primary central nervous system tumors. Rare Tumors.
6:54492014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
McEvoy AW, Harding BN, Phipps KP, Ellison
DW, Elsmore AJ, Thompson D, Harkness W and Hayward RD: Management
of choroid plexus tumours in children: 20 Years experience at a
single neurosurgical centre. Pediatr Neurosurg. 32:192–199. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rickert CH and Paulus W: Tumors of the
choroid plexus. Microsc Res Tech. 52:104–111. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Turkoglu E, Kertmen H, Sanli AM, Onder E,
Gunaydin A, Gurses L, Ergun BR and Sekerci Z: Clinical outcome of
adult choroid plexus tumors: Retrospective analysis of a single
institute. Acta Neurochir (Wien). 156:1461–1478. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kourbeti IS, Jacobs AV, Koslow M,
Karabetsos D and Holzman RS: Risk factors associated with
postcraniotomy meningitis. Neurosurgery. 60:317–325; discussion
325–316. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
O'Malley MR and Haynes DS: Assessment and
management of meningitis following cerebellopontine angle surgery.
Curr Opin Otolaryngol Head Neck Surg. 16:427–433. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Farnedi A, Rossi S, Bertani N, Gulli M,
Silini EM, Mucignat MT, Poli T, Sesenna E, Lanfranco D,
Montebugnoli L, et al: Proteoglycan-based diversification of
disease outcome in head and neck cancer patients identifies
NG2/CSPG4 and syndecan-2 as unique relapse and overall survival
predicting factors. BMC Cancer. 15:3522015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nicolosi PA, Dallatomasina A and Perris R:
Theranostic impact of NG2/CSPG4 proteoglycan in cancer.
Theranostics. 5:530–544. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tateno T, Nakano-Tateno T, Ezzat S and Asa
SL: NG2 targets tumorigenic Rb inactivation in Pit1-lineage
pituitary cells. Endocr Relat Cancer. 23:445–456. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yadavilli S, Hwang EI, Packer RJ and
Nazarian J: The role of NG2 proteoglycan in glioma. Transl Oncol.
9:57–63. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Carrasco-Garcia E, Santos JC, Garcia I,
Brianti M, García-Puga M, Pedrazzoli J Jr, Matheu A and Ribeiro ML:
Paradoxical role of SOX2 in gastric cancer. Am J Cancer Res.
6:701–713. 2016.PubMed/NCBI
|
|
20
|
Li Q, Liu F, Zhang Y, Fu L, Wang C, Chen
X, Guan S and Meng X: Association of SOX2 and nestin DNA
amplification and protein expression with clinical features and
overall survival in non-small cell lung cancer: A systematic review
and meta-analysis. Oncotarget. 7:34520–34531. 2016.PubMed/NCBI
|
|
21
|
Schaefer T, Wang H, Mir P, Konantz M,
Pereboom TC, Paczulla AM, Merz B, Fehm T, Perner S, Rothfuss OC, et
al: Molecular and functional interactions between AKT and SOX2 in
breast carcinoma. Oncotarget. 6:43540–43556. 2015.PubMed/NCBI
|
|
22
|
van Olphen S, Biermann K, Spaander MC,
Kastelein F, Steyerberg EW, Stoop HA, Bruno MJ and Looijenga LH:
SOX2 as a novel marker to predict neoplastic progression in
Barrett's esophagus. Am J Gastroenterol. 110:1420–1428. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stallcup WB: The NG2 proteoglycan: Past
insights and future prospects. J Neurocytol. 31:423–435. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sakry D and Trotter J: The role of the NG2
proteoglycan in OPC and CNS network function. Brain Res.
1638:161–166. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang FJ, You WK, Bonaldo P, Seyfried TN,
Pasquale EB and Stallcup WB: Pericyte deficiencies lead to aberrant
tumor vascularizaton in the brain of the NG2 null mouse. Dev Biol.
344:1035–1046. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fukushi J, Makagiansar IT and Stallcup WB:
NG2 proteoglycan promotes endothelial cell motility and
angiogenesis via engagement of galectin-3 and alpha3beta1 integrin.
Mol Biol Cell. 15:3580–3590. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brekke C, Lundervold A, Enger PØ, Brekken
C, Stålsett E, Pedersen TB, Haraldseth O, Krüger PG, Bjerkvig R and
Chekenya M: NG2 expression regulates vascular morphology and
function in human brain tumours. Neuroimage. 29:965–976. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Albright JE, Stojkovska I, Rahman AA,
Brown CJ and Morrison BE: Nestin-positive/SOX2-negative cells
mediate adult neurogenesis of nigral dopaminergic neurons in mice.
Neurosci Lett. 615:50–54. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rizzino A and Wuebben EL: Sox2/Oct4: A
delicately balanced partnership in pluripotent stem cells and
embryogenesis. Biochim Biophys Acta. 1859:780–791. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Le N, Nagarajan R, Wang JY, Araki T,
Schmidt RE and Milbrandt J: Analysis of congenital hypomyelinating
Egr2Lo/Lo nerves identifies Sox2 as an inhibitor of Schwann cell
differentiation and myelination. Proc Natl Acad Sci USA. 102:pp.
2596–2601. 2005; View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Takahashi K, Tanabe K, Ohnuki M, Narita M,
Ichisaka T, Tomoda K and Yamanaka S: Induction of pluripotent stem
cells from adult human fibroblasts by defined factors. Cell.
131:861–872. 2007. View Article : Google Scholar : PubMed/NCBI
|
